Page last updated: 2024-11-13

4-epianhydrotetracycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-epianhydrotetracycline: impurity in pahrmaceutical preparations of tetracycline; RN refers to (4S-(4alpha,4aalpha,12aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54678401
CHEMBL ID1962867
SCHEMBL ID10216304
MeSH IDM0066092

Synonyms (27)

Synonym
4-epianhydrotetracycline
epianhydrotetracycline
unii-680vdl31mx
(4r-(4alpha,4abeta,12abeta))-4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-2-naphthacenecarboxamide
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-, (4r-(4alpha,4abeta,12abeta))-
7518-17-4
4-epi-5a,6-anhydrotetracycline
680vdl31mx ,
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-, 4-epimer
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-, (4r-(4.alpha.,4a.beta.,12a.beta.))-
4-epianhydrotetracycline [usp impurity]
1665-57-2
tetracycline impurity d [ep impurity]
epi-anhydrotetracycline
tetracycline hydrochloride impurity d [ep impurity]
chlortetracycline hydrochloride impurity i [ep impurity]
anhydroepitetracycline
lymecycline impurity d [ep impurity]
2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-, (4r,4as,12as)-
(4r,4as,12as)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,11,12a-hexahydrotetracene-2-carboxamide
SCHEMBL10216304
CHEMBL1962867
(4r,4as,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-6-methyl-3,12-dioxo-4a,5-dihydro-4h-tetracene-2-carboxamide
2-naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-,(4r,4as,12as)-
DTXSID00873791
Q27264184
epianhydrotetracycline (hydrochloride)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Anhydrotetracycline (AHTC) is the major toxic decomposition product of the antibiotic tetracycline."( Metal complexes of anhydrotetracycline. 2. Absorption and circular dichroism study of Mg(II), Al(III), and Fe(III) complexes. Possible influence of the Mg(II) complex on the toxic side effects of tetracycline.
Beraldo, H; Demicheli, C; Garnier-Suillerot, A; Machado, FC, 1995
)
0.29
" The more toxic transformation products of TC, 4-epitetracycline (ETC), anhydrotetracycline (ATC) and 4-epianhydrotetracycline (EATC) are also widely detected."( Toxicity of tetracycline and its transformation products to a phosphorus removing Shewanella strain.
Li, N; Long, S; Pavlostathis, SG; Sun, P; Xiang, F; Yang, Y; Zhao, L, 2020
)
0.77
" Cadmium (Cd) is a common heavy metal contaminant and has highly toxic to organisms, plants and humans even at low doses."( Toxicity of single and combined 4-epianhydrotetracycline and cadmium at environmentally relevant concentrations on the zebrafish embryos (Danio rerio).
Lin, Y; Wang, M; Wu, L; Yu, J, 2023
)
1.19

Dosage Studied

ExcerptRelevanceReference
" In agreement with others, we find that Tn10 tet exhibits a negative gene dosage effect."( Multicopy Tn10 tet plasmids confer sensitivity to induction of tet gene expression.
Bertrand, KP; Moyed, HS; Nguyen, TT, 1983
)
0.27
" Dose-response studies show that doxycycline is the most potent-analogue in abolishing tTA activity."( Delay in resumption of the activity of tetracycline-regulatable promoter following removal of tetracycline analogues.
A-Mohammadi, S; Alvarez-Vallina, L; Ashworth, LJ; Hawkins, RE, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (114)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (8.77)18.7374
1990's14 (12.28)18.2507
2000's43 (37.72)29.6817
2010's34 (29.82)24.3611
2020's13 (11.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.56 (24.57)
Research Supply Index4.77 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other116 (99.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]